Resistin and adiponectin, recently discovered adipokines, are secreted from adipose tissue, with postulated opposing functions in insulin resistance and inflammation. More recently, an abundance of resistin was detected in macrophages, which suggests its important role in inflammation. The aim of this study was to clarify circulating serum adipokine levels in women with periodontitis. Thirty-four women with moderate to severe periodontitis and 42 control individuals with healthy gingiva (50- to 59-year-old women) were selected. The serum level of adipokines was analyzed between groups, along with the obesity index, smoking status, and age. Having periodontitis was significantly associated with an increased level of resistin, both in bivariate (OR, 3.0; 95% CI, 1.2–7.6) and multivariate (adjusted OR, 3.1; 95% CI, 1.1–8.6) analyses. The association of periodontitis with a decreased level of adiponectin did not reach statistical significance. It was concluded that an increased serum resistin level in middle-aged Japanese women with periodontitis may affect systemic health.
Get full access to this article
View all access options for this article.
References
1.
Brown LJ, Brunelle JA, Kingman A -1996-. Periodontal status in the United States, 1988–1991: prevalence, extent, and demographic variation. J Dent Res75-Spec Iss-:672–683.
2.
Fantuzzi G -2005-. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol115:911–919.
3.
Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, et al. -2006-. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care29:1357–1362.
4.
Janket SJ, Wightman A, Baird AE, Van Dyke TE, Jones JA -2005-. Does periodontal treatment improve glycemic control in diabetic patients? A meta-analysis of intervention studies. J Dent Res84:1154–1159.
5.
Kopelman PG -2000-. Obesity as a medical problem. Nature404:635–643.
6.
Kubo M, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Hirakata H, et al. -1999-. Effect of hyperinsulinemia on renal function in a general Japanese population: the Hisayama study. Kidney Int55:2450–2456.
7.
Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, et al. -2003-. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab88:4848–4856.
8.
Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA -2004-. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med1-2-:e45: 161–168.
9.
Linden G, Patterson C, Evans A, Kee F -2007-. Obesity and periodontitis in 60–70-year-old men. J Clin Periodontol34:461–466.
10.
Löe H -1993-. Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care16:329–334.
11.
Migita K, Maeda Y, Miyashita T, Kimura H, Nakamura M, Ishibashi H, et al. -2006-. The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol24:698–701.
12.
Osawa H, Ochi M, Kato K, Yamauchi J, Nishida W, Takata Y, et al. -2007-. Serum resistin is associated with the severity of microangiopathies in type 2 diabetes. Biochem Biophys Res Commun355:342–346.
13.
Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gómez-Reino JJ, et al. -2006-. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis65:1198–1201.
14.
Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G, et al. -2006-. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab91:1081–1086.
15.
Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. -2003-. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun300:472–476.
16.
Pittas AG, Joseph NA, Greenberg AS -2004-. Adipocytokines and insulin resistance. J Clin Endocrinol Metab89:447–452.
17.
Saito T, Shimazaki Y -2007-. Metabolic disorders related to obesity and periodontal disease. Periodontol 200043:254–266.
18.
Saito T, Shimazaki Y, Sakamoto M -1998-. Obesity and periodontitis. N Engl J Med339:482–483.
19.
Saito T, Shimazaki Y, Kiyohara Y, Kato I, Kubo M, Iida M, et al. -2004-. The severity of periodontal disease is associated with the development of glucose intolerance in non-diabetics: the Hisayama study. J Dent Res83:485–490.
20.
Saito T, Shimazaki Y, Kiyohara Y, Kato I, Kubo M, Iida M, et al. -2005-. Relationship between obesity, glucose tolerance, and periodontal disease in Japanese women: the Hisayama study. J Periodontal Res40:346–353.
21.
Shimazaki Y, Saito T, Yonemoto K, Kiyohara Y, Iida M, Yamashita Y -2007-. Relationship of metabolic syndrome to periodontal disease in Japanese women: the Hisayama study. J Dent Res86:271–275.
22.
Shojima N, Ogihara T, Inukai K, Fujishiro M, Sakoda H, Kushiyama A, et al. -2005-. Serum concentrations of resistin-like molecules beta and gamma are elevated in high-fat-fed and obese db/db mice, with increased production in the intestinal tract and bone marrow. Diabetologia48:984–992.
23.
Steppan CM, Lazar MA -2002-. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab13:18–23.
24.
Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. -2001a-. The hormone resistin links obesity to diabetes. Nature409:307–312.
25.
Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, et al. -2001b-. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA98:502–506.
26.
Takeishi Y, Niizeki T, Arimoto T, Nozaki N, Hirono O, Nitobe J, et al. -2007-. Serum resistin is associated with high risk in patients with congestive heart failure—a novel link between metabolic signals and heart failure. Circ J71:460–464.
27.
Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS -1997-. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature389:610–614.
28.
Yamaguchi N, Argueta JG, Masuhiro Y, Kagishita M, Nonaka K, Saito T, et al. -2005-. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett579:6821–6826.
29.
Yamaguchi N, Kukita T, Li YJ, Martinez Argueta JG, Saito T, Hanazawa S, et al. -2007-. Adiponectin inhibits osteoclast formation stimulated by lipopolysaccharide from Actinobacillus actinomycetemcomitans.FEMS Immunol Med Microbiol49:28–34.
30.
Yaturu S, Reddy RD, Rains J, Jain SK -2007-. Plasma and urine levels of resistin and adiponectin in chronic kidney disease. Cytokine37:1–5.
31.
Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. -2000-. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood96:1723–1732.
